Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT

Abroad (travel likely)RecruitingPHASE2

Conditions

Myeloid Leukemia · Myelodysplastic Syndromes

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Deparment of Hematology, Peking University People's Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Xiaojun Huang, doctor) · xjrm@medmail.com.cn · 8601088326666

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia

Abroad (travel likely)RecruitingPHASE2

Duarte, United States

National Longitudinal Cohort of Hematological Diseases

Multiple Myeloma · Acute Myeloid Leukemia · Hemophilia

Abroad (travel likely)Recruiting

Tianjin, China

Home Blood Transfusions

Hematologic Malignancy · Myelodysplastic Syndromes · Acute Myeloid Leukemia

Abroad (travel likely)Recruiting

Philadelphia, United States

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE2

Tucson, United States · Tucson, United States